Study #2022-0528
CanceR signal OrigiN (CSO) prediction in cancer of Unknown primary (CUP) Syndrome using circulating cell-free tumor DNA (ctDNA) Profiling: a prospective observational and feasibility Study.
MD Anderson Study Status
Enrolling
Treatment Agent
Description
CSO prediction in CUP Syndrome using ctDNA Profiling.
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Unknown Sites
Study phase:
Not applicable
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-798-1207
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.